Biomx Inc (PHGE)

$0.22

Market is closed - opens 7 PM, 29 Jul 2024

Performance

  • $0.22
    $0.23
    $0.22
    downward going graph

    0.0%

    Downside

    Day's Volatility :6.3%

    Upside

    6.3%

    downward going graph
  • $0.19
    $0.86
    $0.22
    downward going graph

    15.18%

    Downside

    52 Weeks Volatility :78.18%

    Upside

    74.27%

    downward going graph

Returns

PeriodBiomx IncIndex (Russel 2000)
3 Months
-34.86%
0.0%
6 Months
-13.96%
0.0%
1 Year
-43.0%
0.0%
3 Years
-94.93%
-20.2%

Highlights

Market Capitalization
41.1M
Book Value
- $0.16
Earnings Per Share (EPS)
-0.59
Profit Margin
0.0%
Operating Margin TTM
0.0%
Return On Assets TTM
-25.59%
Return On Equity TTM
-190.33%
Revenue TTM
0.0
Revenue Per Share TTM
0.0
Quarterly Revenue Growth YOY
0.0%
Gross Profit TTM
0.0
EBITDA
-24.3M
Diluted Eps TTM
-0.59
Quarterly Earnings Growth YOY
0.0
EPS Estimate Current Year
0.0
EPS Estimate Next Year
0.0
EPS Estimate Current Quarter
0.0
EPS Estimate Next Quarter
0.0

Analyst Recommendation

Buy
    87%Buy
    12%Hold
    0
    0%Sell
Based on 8 Wall street analysts offering stock ratings for Biomx Inc(by analysts ranked 0 to 5 stars)
Based on 8 analyst
  • Current
  • 1M Ago
  • 3M Ago
Buy
7
7
7
Hold
1
1
1
Sell
00
00
00

Technicals Summary

Sell

Neutral

Buy

Biomx Inc is currently not in a favorable trading position ( SELL ) according to technical analysis indicators.

More on Technical Analysis

Peers

Company Name1 Month6 Month1 Year3 Years5 Years
Biomx Inc
Biomx Inc
-32.94%
-13.96%
-43.0%
-94.93%
-97.75%
Moderna, Inc.
Moderna, Inc.
-1.67%
18.26%
-0.21%
-64.15%
752.69%
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
-0.46%
13.21%
45.59%
84.19%
244.2%
Novo Nordisk A/s
Novo Nordisk A/s
-11.0%
18.31%
61.56%
186.46%
423.59%
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
3.85%
14.43%
39.88%
147.45%
195.07%
Company NameP/E RatioP/B RatioPEG RatioEPSROEROADiv YieldBVPS
Biomx Inc
Biomx Inc
NA
NA
NA
0.0
-1.9
-0.26
NA
-0.16
Moderna, Inc.
Moderna, Inc.
24.73
NA
0.0
-7.19
-0.38
-0.16
NA
33.47
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
31.35
31.35
1.46
44.44
0.15
0.08
NA
250.15
Novo Nordisk A/s
Novo Nordisk A/s
44.28
44.28
2.36
3.43
1.0
0.25
0.01
22.18
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
31.85
31.85
0.53
16.98
0.24
0.13
NA
71.8
Company NameAnalyst ViewMarket Cap5 Years Return %PE RatioProfit Margin
Biomx Inc
Biomx Inc
Buy
$41.1M
-97.75%
NA
0.0%
Moderna, Inc.
Moderna, Inc.
Buy
$45.3B
752.69%
24.73
-115.82%
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
Buy
$116.9B
244.2%
31.35
29.45%
Novo Nordisk A/s
Novo Nordisk A/s
Buy
$572.0B
423.59%
44.28
36.55%
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
Buy
$126.7B
195.07%
31.85
39.46%

Insights on Biomx Inc

  • Increasing Revenue

    Revenue is up for the last 5 quarters, -134.0K → -87.0K (in $), with an average increase of 13.0% per quarter

  • Decreasing Net Profit

    Netprofit is down for the last 3 quarters, -382.0K → -5.49M (in $), with an average decrease of 668.7% per quarter

  • Vs NVO

    In the last 1 year, Novo Nordisk A/s has given 61.6% return, outperforming this stock by 104.6%

  • Vs NVO

    In the last 3 years, Novo Nordisk A/s has given 186.5% return, outperforming this stock by 281.4%

Company Information

biomx is a microbiome drug discovery company developing customized phage therapies that target and destroy harmful bacteria in chronic diseases such as inflammatory bowel disease (ibd) and cancer. we discover and validate proprietary bacterial targets and customize our natural and engineered phage compositions against these targets. the company’s platforms use computational and synthetic biology and cutting-edge research from profs. rotem sorek, ph.d., eran elinav, m.d., ph.d., and eran segal, ph.d., of the weizmann institute of science; and professor timothy k. lu, m.d., ph.d., of the massachusetts institute of technology. investors in the company include orbimed israel incubator lp, johnson & johnson development corporation inc., takeda ventures, inc., seventure partners, mirae asset global investments, and sbi.

Organization
Biomx Inc
Employees
58
CEO
Mr. Jonathan Eitan Solomon MBA
Industry
Health Technology

Discover More

FAQs